Ernexa Therapeutics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $5.4M
- Price
- $4.95
- % Change (Daily % change from the live per-ticker quote feed.)
- +9.51%
- Volume
- 71.1K
About
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Quick stats
Shares outstanding1.1M
Computed float690.7K
Float / shares63.8%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000748592
Websitehttps://www.ernexatx.com
AI Summary
AI-generated1/16
minorbullishboard change
Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage
Ernexa Therapeutics appointed David Polinsky to its Board of Directors, adding 25 years of biotech leadership and capital markets expertise.
Polinsky currently serves as CFO of Rafael Holdings and co-founded Cornerstone Pharmaceuticals, bringing significant experience in corporate strategy and governance.
The company remains on track to submit an IND for its lead asset ERNA-101 in Q3 2026 and initiate a Phase 1 study in Q4 2026.